Armistice Capital and Steven Boyd Disclose 2.92M Shares (8.70%) of ACXP

Rhea-AI Filing Summary

Armistice Capital and Steven Boyd report passive ownership of 8.70% of Acurx Pharmaceuticals common stock. The filing states Armistice Capital, as investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 2,917,975 shares. The Master Fund is the direct holder while Armistice Capital exercises investment and voting power under an Investment Management Agreement; the Master Fund disclaims beneficial ownership arising solely from that agreement. The filing is made on Schedule 13G indicating the holdings are reported as passive.

Positive

• Material disclosure of substantial stake: Reporting Persons hold 2,917,975 shares representing 8.70% of the class, meeting SEC materiality thresholds.
• Passive classification: Filed on Schedule 13G, indicating the holders report the position as ordinary-course and not intended to change or influence control.

Negative

• No statement of future intentions: The filing contains no plans or clarifying detail about future trading or strategic intentions that could reduce investor uncertainty.
• Shared voting power only: Reporting Persons report 0 shares of sole voting power, indicating control is shared rather than unilateral.

Insights

Securities Analyst

TL;DR: Armistice Capital and its managing member report an 8.70% passive stake in ACXP via a managed fund.

Armistice Capital, through its Master Fund, holds 2,917,975 shares representing 8.70% of Acurx Pharmaceuticals common stock and reports shared voting and dispositive power. The Schedule 13G classification signals the Reporting Persons state the stake is passive and not intended to influence control. For investors, a disclosed >5% holder is material because it identifies a sizable investor with the ability to influence outcomes indirectly, though the filing contains no indication of activist intent or transactions beyond the holding.

Corporate Governance Specialist

TL;DR: A material ownership disclosure with shared control via an investment adviser structure; filing asserts ordinary-course, non-control purpose.

The filing clarifies the chain of ownership: the Master Fund is the direct holder while Armistice Capital and Steven Boyd exercise voting and investment powers under an Investment Management Agreement. The Master Fund expressly disclaims beneficial ownership under that agreement. The joint filing statement documents shared responsibility for amendments. There are no statements of intent to change or influence control in this document.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Acurx Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

007025802

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 007025802

1

Names of Reporting Persons

Armistice Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,917,975.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,917,975.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,917,975.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.70 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 007025802

1

Names of Reporting Persons

Steven Boyd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,917,975.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,917,975.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,917,975.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.70 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Acurx Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 259 LIBERTY AVENUE, STATEN ISLAND, NY, 10305
Item 2.
(a)	Name of person filing: Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
(b)	Address or principal business office or, if none, residence: Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
(c)	Citizenship: Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 007025802
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,917,975
(b)	Percent of class: 8.70 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,917,975
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,917,975 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Armistice Capital, LLC

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd - Managing Member
Date:	08/14/2025

Steven Boyd

Signature:	/s/ Steven Boyd
Name/Title:	Steven Boyd
Date:	08/14/2025

Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

Who reported the 8.70% stake in Acurx Pharmaceuticals (ACXP)?

The filing was made by Armistice Capital, LLC and Steven Boyd, reporting a combined beneficial ownership of 2,917,975 shares equal to 8.70% of the class.

What type of SEC filing did Armistice Capital submit for ACXP?

They filed a Schedule 13G, which indicates the reported stake is held in the ordinary course of business and is reported as passive.

How much voting and dispositive power do the reporting persons have over ACXP shares?

The reporting persons report 2,917,975 shares of shared voting power and shared dispositive power, with 0 shares of sole voting or dispositive power.

Is the Master Fund the direct holder of the ACXP shares?

Yes. The filing states the Armistice Capital Master Fund Ltd. is the direct holder and Armistice Capital is the investment manager exercising voting and investment power.

Does the filing state the holders intend to influence control of ACXP?

No. The certification in the filing states the securities were not acquired for the purpose of changing or influencing control, consistent with a Schedule 13G filing.